DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20183013

Utility of apremilast in the treatment of psoriasis

K. Snehalatha, Roshni Ravindranathan, D. K. Sriram, Melvin George

Abstract


Psoriasis is an autoimmune disease that affects more than one bodily system with predominantly skin and also joint manifestations affecting almost 2% of the world population that occurs primarily due to immune dysregulation. Apremilast is an oral, selective inhibitor of phosphodiesterase-4 (PDE4) enzymes. Inhibition of PDE-4 results in specific elevation of cAMP, an innately occurring intracellular secondary messenger that functions as a modulator of inflammatory responses. The drug is taken orally in strengths of 10, 20 and 30 mg. The drug may be a suitable alternative to different systemic therapies. Apremilast is a much-needed molecule for the treatment of psoriasis that is resistant to first line therapy and also useful in combination therapies.


Keywords


Apremilast, Psoriasis

Full Text:

PDF

References


John W. Ely, And Mary Seabury Stone, The generalized rash: Part II. Diagnostic approach. Am Fam Physician. 2010 Mar 15;81(6):735-9.

Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Aca Dermatol. 2008 May 1;58(5):826-50.

Papadavid E, Rompoti N, Theodoropoulos K, Kokkalis G, Rigopoulos D. Real‐world data on the efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis. J Euro Aca Dermatol Venereol. 2018 Feb 1.

Bubna AK. Apremilast: A dermatologic perspective. Indian J Drugs Dermatol. 2016;2:75-82.

Vangipuram R, Alikhan A. Apremilast for the management of moderate to severe plaque psoriasis. Expert review clinical Pharmacol. 2017;10(4):349-60.

Boehncke WH, Schön MP. Psoriasis. The Lancet. 2015;386(9997):983-94.

Europe Medicines Agencies. Assessment report: Otezla, International non-proprietary name: apremilast. Available at: http://www.ema.europa.eu /d ocs/en_GB/document_library/EPAR_-_Public_ asses sment_report/human/003746/WC500182629.pdf.

Oral otezla (apremilast) approved by the U.S. Food and drug administration for the treatment of patients with moderate to severe plaque psoriasis. Available at: http://ir.celgene.com/releasedetail.cfm?releaseid=872240. Retrieved 29 October 2014.

Sumantran VN, Mishra P, Bera R, Sudhakar N. Microarray analysis of differentially-expressed genes encoding CYP450 and phase II drug metabolizing enzymes in psoriasis and melanoma. Pharmaceutics. 2016 Feb 17;8(1):4.

Deeks ED-Apremilast: A review in psoriasis and psoriatic arthritis Drugs. 2015;75(12):1393-403.

Torres T, Puig L. Apremilast: a novel oral treatment for psoriasis and psoriatic arthritis. American journal of clinical dermatology. 2017 Jun:1-0.

Australian public assessment report for apremilast proprietary product name: Otezla, PM-2013-04920-1-3. Available at: https://www.tga.gov.au/sites/default/files/auspar-apremilast-151022.pdf

Crowley J, Thaçi D, Joly P, Peris K, Papp KA, Goncalves J, et al. Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for≥ 156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Aca Dermatol. 2017 Aug 1;77(2):310-7.

Cather JC, Horn EJ. Apremilast in the treatment of moderate-to-severe plaque psoriasis: results from the ESTEEM studies. Clin Inves. 2015 Sep;5(9):777-91.

Papp K, Cather JC, Rosoph L, Sofen H, Langley RG, Matheson RT, Hu C, Day RM. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. The Lancet. 2012 Aug 25;380(9843):738-46.

Medscape. Otezla (aprelimast) dosing, indications, interactions, adverse effects, and more. Available from: https://reference.medscape.com/drug/otezla-apremilast-999915.

Reich K, Gooderham M, Green L, Bewley A, Zhang Z, Khanskaya I, et al. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo‐controlled trial (LIBERATE). J Euro Aca Dermatol Venereol. 2017 Mar;31(3):507-17.

RxList. Otezla (apremilast tablets): Side effects, interactions, warning, dosage and uses. Available from: https://www.rxlist.com/otezla-drug.htm#side_ effects_interactions.

EMC. Otezla 30mg tablets-summary of product characteristics (smpc)-(emc). Available at: https://www.medicines.org.uk/emc/product/3648.

Zerilli T, Ocheretyaner E. Apremilast (Otezla): a new oral treatment for adults with psoriasis and psoriatic arthritis. Pharmacy and Therapeutics. 2015 Aug;40(8):495.